Mackay Shields LLC’s Filana Therapeutics FLNA Stock Holding History

Mackay Shields LLC’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,300	Closed	-$283K	–	1216
2021 Q1	$283K	Buy	+6,300	New	+$248K	﹤0.01%	1346

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Mackay Shields LLC's FLNA Position: Q2 2021 in Review

Mackay Shields LLC sold out of Filana Therapeutics (FLNA) in Q2 2021, closing a stake of 6,300 shares — an estimated $283K sold.

Mackay Shields LLC first reported a position in FLNA in Q1 2021 and held it in 1 quarter. The position peaked at $283K in Q1 2021. 169 funds tracked by Wall St. Rank hold FLNA as of Q2 2021.

Mackay Shields LLC reported no remaining Filana Therapeutics position as of Q2 2021 after selling out during the quarter.
Mackay Shields LLC sold 6,300 Filana Therapeutics shares in Q2 2021, an estimated $283K.
Mackay Shields LLC first reported a position in Filana Therapeutics in Q1 2021 and held it in 1 quarter.
Mackay Shields LLC's Filana Therapeutics position peaked at $283K in Q1 2021.
169 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.